Mary Ann Anderson

Zanubrutinib for the treatment of patients with del(17p) and/or TP53 CLL/SLL: analysis across clinical studies.

Infections in the first 30-days after CAR-T therapy in Patients Not Receiving Fluoroquinolone Prophylaxis.

Venetoclax retreatment in chronic lymphocytic leukemia is biologically rational and clinically effective.

Venetoclax and ibrutinib induces durable clinical responses in marginal zone lymphoma.

Cognitive impairment in hematology patients planned for chimeric antigen receptor T-cell therapy.

Australia and New Zealand consensus statement on the cardiovascular management of patients with chronic lymphocytic leukaemia treated with Bruton's tyrosine kinase inhibitors.

Real-world utilization of Bruton tyrosine kinase inhibitors in relapsed/refractory chronic lymphocytic leukemia in Australia.

Predicting infection risk following CAR-T using the bedside CAR-HEMATOTOX score: performance in an Australian cohort

Infections in patients with lymphoma treated with bispecific antibodies: a systematic review and meta-analysis.

Seven-year outcomes of venetoclax-ibrutinib therapy in mantle cell lymphoma: durable responses and treatment-free remissions.

Sonrotoclax and Zanubrutinib as Frontline Treatment for CLL Demonstrates High MRD Clearance Rates with Good Tolerability: Data from an Ongoing Phase 1/1b Study BGB-11417-101

Venetoclax dose escalation rapidly activates a BAFF/BCL-2 survival axis in chronic lymphocytic leukemia.

Neuropsychological outcomes of patients with haematological malignancies undergoing chimeric antigen receptor T-cell therapy: protocol for a prospective study.

Seropositivity against vaccine preventable infections in the early post chimeric antigen receptor T-cell period: Preservation of vaccine-associated antibodies between 0 and 6 months.

Updated quality of life data from the phase 3b VENICE II trial: patients with relapsed or refractory chronic lymphocytic leukemia receiving venetoclax monotherapy.

Combination Treatment with Sonrotoclax (BGB-11417), a Second-Generation BCL2 Inhibitor, and Zanubrutinib, a Bruton Tyrosine Kinase (BTK) Inhibitor, Is Well Tolerated and Achieves Deep Responses in Patients with Treatment-Naïve Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (TN-CLL/SLL): Data from an Ongoing Phase 1/2 Study

Psychiatric, cognitive, psychosocial, and neurological outcomes of chimeric antigen receptor T-cell therapy: protocol for a prospective study

Complexity of baseline cognitive and psychological status in haematology patients planned for chimeric antigen receptor T-cell therapy

Single-cell sequencing demonstrates complex resistance landscape in CLL and MCL treated with BTK and BCL2 inhibitors.

Neuroimaging findings in immune effector cell associated neurotoxicity syndrome after chimeric antigen receptor T-cell therapy.

Impact of venetoclax monotherapy on the quality of life of patients with relapsed or refractory chronic lymphocytic leukemia: results from the phase 3b VENICE II trial.

Health-related quality of life for patients with chronic lymphocytic leukaemia - A critical outcome measure in the era of highly effective therapies.

Interim Results from the First Clinical Study of CC-95251, an Anti-Signal Regulatory Protein-Alpha (SIRPα) Antibody, in Combination with Rituximab in Patients with Relapsed and/or Refractory Non-Hodgkin Lymphoma (R/R NHL)

BTK inhibitor therapy is effective in patients with CLL resistant to venetoclax

Comprehensive characterization of single cell full-length isoforms in human and mouse with long-read sequencing

Acquisition of the Recurrent Gly101Val Mutation in BCL2 Confers Resistance to Venetoclax in Patients with Progressive Chronic Lymphocytic Leukemia.

Dynamic molecular monitoring reveals that SWI-SNF mutations mediate resistance to ibrutinib plus venetoclax in mantle cell lymphoma.

Structures of BCL-2 in complex with venetoclax reveal the molecular basis of resistance mutations.

BTK Leu528Trp - a Potential Secondary Resistance Mechanism Specific for Patients with Chronic Lymphocytic Leukemia Treated with the Next Generation BTK Inhibitor Zanubrutinib

Venetoclax plus rituximab in relapsed or refractory chronic lymphocytic leukaemia: a phase 1b study

RUI: Exploring Synthesis, Tailoring Structure, Evaluating Properties, and Enabling Patterning of Surface-Anchored Framework Assemblies

RUI: Enabling Rational Design of Smart Interfaces Incorporating Metal-Organic Coordinated Assemblies

RUI: Enabling Rational Design of Smart Interfaces Incorporating Metal-Organic Coordinated Assemblies

Japanese Language Fellowship for Erik K. Webb

Scaling Problems in Hydrogeological Modeling

Mathematical Models of Groundwater-Surface Water Systems